Genta Incorporated Announces Results of Tesetaxel Confirmatory Trial in Patients With Advanced Gastric Cancer

BERKELEY HEIGHTS, N.J., May 24, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (GNTA) today announced results from the Company's Phase 2, confirmatory, clinical trial of tesetaxel as 2nd-line treatment of patients with advanced gastric cancer. The trial was conducted at M.D. Anderson Cancer Center, Houston, TX, in collaboration with Northwestern University, Chicago, IL, the University of Pennsylvania, Philadelphia, PA, and the Severance Hospital, Seoul, Korea. Detailed results will be presented next month at the annual meeting of the American Society of Clinical Oncology (ASCO). Tesetaxel is the leading oral taxane in clinical development.